Tor Savidge, Ph.D.
Picture
Tor Savidge, Ph.D.
Professor
Positions
- Professor
-
Department of Pathology & Immunology
草榴社区入口
Houston, TX US
Professional Statement
My laboratory is actively researching Clostridium difficile pathogenesis and we were the first to identify toxin B as the major virulence factor in human intestine. We also identified a novel innate host defense mechanism against microbial toxin and pioneered new therapeutic concepts which we termed 鈥渁llosteric therapeutics鈥.My research has also played a central role in discovering novel glial cell functions in the gut.
Websites
Selected Publications
- Savidge TC, Urvil P, Oezguen N, Ali K, Choudhury A, Acharya V, Pinchuk I, Torres AG, English RD, Wiktorowicz JE, Loeffelholz M, Kumar R, Shi L, Nie W, Braun W, Herman B, Hausladen A, Feng H, Stamler JS, Pothoulakis C "." Nat. Med.. 2011 Sep;17(9):1136-41. Pubmed PMID:
- Chen D, Savidge T. "." Science. 2015 Aug 28;349(6251):936. Pubmed PMID:
- Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. "." Sci Adv. 2016 Mar 25;2(3) Pubmed PMID:
- Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV "." Cell. 1998 Apr 17;93(2):189-201. Pubmed PMID:
- Cornet A, Savidge TC, Cabarrocas J, Deng WL, Colombel JF, Lassmann H, Desreumaux P, Liblau RS "." Proc. Natl. Acad. Sci. U.S.A.. 2001 Nov 6;98(23):13306-11. Pubmed PMID:
- Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV "." Gastroenterology. 2007 Apr;132(4):1344-58. Pubmed PMID:
- Savidge TC. "." Front Cell Neurosci.. 2016 Jan 8;9(503) Pubmed PMID:
- MacEachern SJ, Patel BA, Keenan CM, Dicay M, Chapman K, McCafferty DM, Savidge TC, Beck PL, MacNaughton WK, Sharkey KA "." Gastroenterology. 2015 Aug;149(2):445-455. Pubmed PMID:
- Mayer EA, Savidge T, Shulman RJ "." Gastroenterology. 2014 May;146(6):1500-1512. Pubmed PMID:
Funding
- Allosteric therapy of the Clostridium difficile toxins - #R01 NIAID AI10094001 (05/01/2012 - 05/31/2017) Grant funding from NIH R01
- The goal of this study is to develop novel allosteric inhibitors for the C. difficile toxins using inositolphosphate analogs and S-nitrosothiol biology.
- Metabolome-Based Biomarkers and Neutraceuticals in Clostridium Difficile Infection. - #R21DK096323-01 (09/15/2014 - 08/31/2015) Grant funding from NIH R21
- The goal of this study is to develop validate metabolomics biomarkers of disease susceptibility to Clostridium difficile.
Skills
- Expert Omics review
- NASA Human Research Roadmap for 2035 Mission to Mars.
- Editorial Board
- American Journal of Physiology (Gastroenterology & Hepatology).
to edit your profile
